Patents by Inventor Fabiola Terzi

Fabiola Terzi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220252617
    Abstract: The present invention relates to methods for the prediction of the progression of chronic kidney disease in a patient. More particularly, the invention relates to the early prediction of the fast progression of chronic kidney disease using specific biomarker signatures in urine sample of patients.
    Type: Application
    Filed: April 19, 2022
    Publication date: August 11, 2022
    Applicants: Hoffmann La-Roche Inc., INSERM
    Inventors: Melanie BROUEILH, Mordi MUORAH, Fabiola TERZI
  • Publication number: 20200096523
    Abstract: The present invention relates to methods for the prediction of the progression of chronic kidney disease in a patient. More particularly, the invention relates to the early prediction of the fast progression of chronic kidney disease using specific biomarker signatures in urine sample of patients.
    Type: Application
    Filed: August 20, 2019
    Publication date: March 26, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Melanie BROUEILH, Mordi MUORAH, Fabiola TERZI
  • Patent number: 10337008
    Abstract: The present invention relates to a method for predicting the progression of chronic kidney disease (CKD) in a patient and also to an inhibitor of NGAL gene expression or an NGAL antagonist for use in the prevention or the treatment of CKD.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: July 2, 2019
    Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Fabiola Terzi, Amandine Viau, Clément Nguyen, Martine Burtin, Khalil El Karoui
  • Publication number: 20180143206
    Abstract: The invention relates to a method for determining whether a renal transplanted patient is at risk of acute rejection, comprising a step of determining the expression level of the CXCL10 polypeptide in a urine sample obtained from said patient until 3-months post-transplantation. The invention also relates to a method for diagnosing antibody-mediated rejection (ABMR) in a renal transplanted patient, comprising a step of determining the expression level of the CXCL10 polypeptide in a urine sample obtained from said patient.
    Type: Application
    Filed: May 4, 2016
    Publication date: May 24, 2018
    Inventors: Dany ANGLICHEAU, Fabiola TERZI, Christophe LEGENDRE
  • Publication number: 20170328914
    Abstract: The present invention relates to methods for the prediction of the progression of chronic kidney disease in a patient. More particularly, the invention relates to the early prediction of the fast progression of chronic kidney disease using specific biomarker signatures in urine sample of patients.
    Type: Application
    Filed: May 25, 2017
    Publication date: November 16, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Melanie Broueilh, Mordi Muorah, Fabiola Terzi
  • Publication number: 20160244764
    Abstract: The present invention relates to a method for predicting the progression of chronic kidney disease (CKD) in a patient and also to an inhibitor of NGAL gene expression or an NGAL antagonist for use in the prevention or the treatment of CKD.
    Type: Application
    Filed: May 12, 2016
    Publication date: August 25, 2016
    Applicant: Institut National de la Sante et de la Recherche Medicale
    Inventors: Fabiola TERZI, Amandine VIAU, Clément NGUYEN, Martine BURTIN, Khalil EL KAROUI
  • Publication number: 20160130652
    Abstract: The invention relates to the diagnosis of HIV-associated nephropathy (HIVAN) based on determining the expression level of HIV nucleic acids (HIV RNA and/or DNA) in combination with the renal function of a patient. The invention also relates to a method for distinguishing between HIVAN and non-HIVAN kidney disease in a patient based on the expression level of urinary HIV nucleic acids.
    Type: Application
    Filed: May 28, 2014
    Publication date: May 12, 2016
    Inventors: Guillaume CANAUD, Fabiola TERZI, Christine ROUZIOUX
  • Publication number: 20150258127
    Abstract: The present invention relates to the prevention or treatment of antiphospholipid syndrome (APS) in a patient in need thereof (e.g. patients affected with primary APS, a secondary APS, a catastrophic APS (CAPS) or a transplant recipient with antiphospholipid antibodies (APA)). The present invention also relates to the prevention APS-related vascular lesions in said a patient in need thereof. The present invention further relates to PI3K-AKT-mTOR pathway inhibitor for use in inhibiting endothelial m TORC activation triggered by APA in a patient in need thereof.
    Type: Application
    Filed: October 31, 2013
    Publication date: September 17, 2015
    Inventors: Fabiola Terzi, Guillaume Canaud, Frank Bienaime
  • Publication number: 20150018383
    Abstract: The present invention is directed to the use of marker for Akt2 activation in podocytes as a biomarker to predict toxicity of mTOR inhibitors. Another aspect of the invention relates to a method for preventing graft rejection comprising administering a selective mTORC1 or Akt1 inhibitor in a subject in need thereof.
    Type: Application
    Filed: October 12, 2012
    Publication date: January 15, 2015
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Fabiola Terzi, Guillaume Canaud, Franck Ename
  • Publication number: 20140079769
    Abstract: The present invention relates to a method for predicting the progression of chronic kidney disease (CKD) in a patient and also to an inhibitor of NGAL gene expression or an NGAL antagonist for use in the prevention or the treatment of CKD.
    Type: Application
    Filed: October 3, 2011
    Publication date: March 20, 2014
    Inventors: Fabiola Terzi, Amandine Viau, Clément Nguyen, Martine Burtin, Khalil El Karoui